| P50 | author | Hans-Peter Beck-Bornholdt | Q112545938 |
| P2093 | author name string | Willers H | |
| | Dubben HH | |
| | Liertz-Petersen C | |
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study | Q33419683 |
| | Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495. | Q33638656 |
| | Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study | Q34239497 |
| | Radiotherapy of the rhabdomyosarcoma R1H of the rat: recovery from radiation injury in tumour and skin | Q35907194 |
| | The effect of anaesthetics on blood perfusion in transplanted mouse tumours | Q36067970 |
| | Hyperfractionated radiotherapy in brain stem tumors: results of a Pediatric Oncology Group study | Q36347857 |
| | High dose hyperfractionated radiotherapy in the treatment of extremity soft tissue sarcomas | Q36441529 |
| | Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. | Q36838126 |
| | A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments | Q37114846 |
| | Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma | Q38271145 |
| | European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey | Q39633729 |
| | Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies | Q39650657 |
| | Multiple daily fractionation in radiotherapy: Biological rationale and preliminary clinical experiences | Q39708025 |
| | Multiple fractions per day in retrospect; the L-Q model and the tolerance profile | Q39732623 |
| | Experience with twice-a-day fractionation in clinical radiotherapy | Q39977142 |
| | Hyperfractionated radiation in children with rhabdomyosarcoma—Results of an intergroup rhabdomyosarcoma pilot study | Q40442857 |
| | Radiobiological considerations in the design of clinical trials | Q40639129 |
| | The Evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer | Q40978262 |
| | Preliminary results using twice-a-day fractionation in the radiotherapeutic management of advanced cancers of the head and neck | Q41350828 |
| | The use of 'top-up' experiments to investigate the effect of very small doses per fraction in mouse skin | Q41446442 |
| | Dose, time and fractionation: A clinical hypothesis | Q41524871 |
| | Cell Cycle Redistribution as a Factor in Multifraction Irradiation | Q41971590 |
| | Linear-quadratic model underestimates sparing effect of small doses per fraction in rat spinal cord | Q41990070 |
| | Analysis of the probability and risk of cause-specific failure | Q71646037 |
| | About tolerance and quality. An important notice to all radiation oncologists | Q71765787 |
| | Rebuttal: is gambling a serious alternative to evidence-based medicine? | Q71765832 |
| | Late effects of hyperfractionated radiotherapy for head and neck cancer—In response to Drs. Withers and Taylor, IJROBP 32:887–888; 1995 | Q71868346 |
| | Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial | Q72031116 |
| | Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group | Q72117985 |
| | Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer | Q72134633 |
| | Potential pitfalls in the use of p-values and in interpretation of significance levels | Q72138124 |
| | The effect of the overall treatment time of fractionated irradiation on the tumor control probability of a human soft tissue sarcoma xenograft in nude mice | Q72167225 |
| | Inoperable non-small cell lung cancer: a retrospective analysis of 427 patients treated with high-dose radiotherapy | Q72254415 |
| | Is hyperfractionation really better? | Q72292400 |
| | Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. Phase I/II study of the Radiation Therapy Oncology Group 88-05 | Q72399637 |
| | Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage | Q72402893 |
| | Mechanical assay of consequential and primary late radiation effects in murine small intestine: alpha/beta analysis | Q72421688 |
| | Radiotherapy of the rhabdomyosarcoma R1H of the rat: influence of the time interval between two daily fractions during hyperfractionated radiotherapy | Q72421970 |
| | Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer | Q72516751 |
| | Hyperfractionated radiation in the treatment of squamous cell carcinomas of the head and neck: a comparison of two fractionation schedules | Q72535843 |
| | Effect of small doses per fraction in rat spinal cord: influence of initial vs. final top-up doses | Q72591189 |
| | Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens? | Q72661078 |
| | White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02) | Q72789418 |
| | Improved survival of patients with unresectable non-small-cell bronchogenic carcinoma by an innovated high-doseEn-Bloc radiotherapeutic approach | Q72893918 |
| | Fractionation and dose-rate. II. Dose-time relationships in radiotherapy and the validity of cell survival curve models | Q79543766 |
| | Rapid hyperfractionated radiotherapy. Clinical results in 178 advanced squamous cell carcinomas of the head and neck | Q93570083 |
| | Experimental radiotherapy of a rat rhabdomyosarcoma with 15 meV neutrons and 300 kV x-rays. II. Effects of ractionated treatments, applied five times a week for several weeks | Q93805964 |
| | Irradiation therapy with multiple small fractions per day in urinary bladder cancer | Q69923630 |
| | Radiotherapy of the rhabdomyosarcoma R1H of the rat: hyperfractionation--126 fractions applied within 6 weeks | Q69954194 |
| | Hyperfractionation in the radiation therapy of unresectable non-oat cell carcinoma of the lung: preliminary report of a RTOG Pilot Study | Q69964710 |
| | Twice-a-day radiation therapy for supraglottic carcinoma | Q69996204 |
| | Solid tumor models for the assessment of different treatment modalities: XXV. Comparison of the effect of one radiation fraction per day with multiple fractions per day (MFD) given either continuously or intermittently on tumor response and normal t | Q70017028 |
| | Late results of multiple fractions per day (MFD) with misonidazole in advanced cancer of the head and neck. A pilot study of the EORTC radiotherapy group | Q70078853 |
| | Kinetics of cellular inactivation by fractionated and hyperfractionated irradiation in Lewis lung carcinoma | Q70111230 |
| | Influence of treatment time on the response of rat rhabdomyosarcoma R1H to fractionated irradiation | Q70127020 |
| | ASTRO plenary: interfraction interval is a major determinant of late effects, with hyperfractionated radiation therapy of carcinomas of upper respiratory and digestive tracts: results from Radiation Therapy Oncology Group protocol 8313 | Q70178712 |
| | Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships | Q70372719 |
| | Hyperfractionated radiotherapy with or without misonidazole: results of a prospective randomized study in stage III-IV squamous cell carcinoma of the head and neck | Q70389183 |
| | The Cure of Rhabdomyosarcoma BA 1112 with Fractionated Radiotherapy | Q70498188 |
| | The RBE for renal damage after irradiation with 3 MeV neutrons | Q70518948 |
| | Hyperfractionation | Q70543682 |
| | Twice-a-day radiotherapy for squamous cell carcinoma of the head and neck: the University of Florida experience | Q70578727 |
| | Effects of irradiation by single or multiple fractions per day on transplantable murine mammary carcinoma | Q70595562 |
| | Influence of the timing of a concomitant boost during fractionated irradiation of rat rhabdomyosarcoma R1H | Q70644491 |
| | Results of twice-a-day irradiation of squamous cell carcinomas of the head and neck | Q70647757 |
| | Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02 | Q70697040 |
| | Radiotherapy with thrice-a-day fractionation in a short overall time: Clinical experiences | Q70874529 |
| | Radiation therapy for advanced head and neck squamous-cell carcinoma using twice-a-day fractionation | Q71130656 |
| | A new isoeffect curve for change in dose per fraction | Q71223810 |
| | Twice-daily fractionation schemes for advanced head and neck cancer | Q71393446 |
| | Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. | Q43499603 |
| | Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08. | Q43689636 |
| | What has radiation biology contributed to the evolution of radiotherapy? | Q43725761 |
| | Radiotherapy of the rhabdomyosarcoma R1H of the rat: kinetics of cellular inactivation by fractionated irradiation | Q43779918 |
| | Analysis of late complications after rapid hyperfractionated radiotherapy in advanced head and neck cancers | Q43847194 |
| | A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-sm | Q44024922 |
| | Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13. | Q44290742 |
| | In response to bentzen et al., IJROBP 32:1531–1534; 1995 | Q44402789 |
| | Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys | Q44415007 |
| | The EORTC randomized trial on three fractions per day and misonidazole (trial no. 22811) in advanced head and neck cancer: long-term results and side effects | Q44643838 |
| | Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Onc | Q45160651 |
| | A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer | Q45232525 |
| | Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. | Q46026846 |
| | Late effects of hyperfractionated radiotherapy for advanced head and neck cancer: long-term follow-up results of RTOG 83-13. | Q46248787 |
| | Hyperfractionated radiation therapy for gliomas of the brainstem in children and in adults | Q46614114 |
| | Results of a pilot study of hyperfractionated radiation therapy for children with brain stem gliomas | Q48186591 |
| | Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. A Childrens Cancer Group Phase I/II Trial | Q48232854 |
| | Misonidazole combined with hyperfractionation in the management of malignant glioma | Q48632169 |
| | Super fractionation in glioblastoma multiforme-results of a phase II study | Q48892731 |
| | Effect of interfraction interval in hyperfractionated radiotherapy with or without concurrent chemotherapy for stage III nonsmall cell lung cancer. | Q51041257 |
| | The effect of anaesthesia on the radiosensitivity of rat intestine, foot skin and R-1 tumours. | Q51877018 |
| | Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. | Q52596074 |
| | Changes in Mouse Blood Pressure, Tumor Blood Flow, and Core and Tumor Temperatures following Nembutal or Urethane Anesthesia | Q52713217 |
| | Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02. | Q53648698 |
| | Therapeutic gain factors for fractionated radiation treatment of spontaneous murine tumors using fast neutrons, photons plus O2(1) or 3 ATA, or photons plus misonidazole. | Q53737701 |
| | Why actuarial estimates should be used in reporting late normal-tissue effects of cancer treatment ... now! | Q54576057 |
| | Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant glioma--possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. | Q55483140 |
| | Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial | Q55489648 |
| | Dose-response relationships for late radiation effects in the head and neck: Regarding the analysis of the RTOG 8313 trial, fu et al IJROBP 32:577–588; 1995 | Q57618585 |
| | Relationship between early and late normal-tissue injury after postmastectomy radiotherapy | Q57618722 |
| | A Multicomponent X-ray Survival Curve for Mouse Lymphosarcoma Cells irradiated in vivo | Q59079340 |
| | Preliminary results of a hyperfractionated dose escalation study for locally advanced adenocarcinoma of the prostate | Q60148291 |
| | Relative effectiveness of 12-hourly fractionation and a non-uniform X-ray schedule in the optimum fractionation of C3H mouse mammary tumours | Q66955013 |
| | Effect of normobaric oxygen on tumor radiosensitivity: fractionated studies | Q67279690 |
| | Further experience with radiotherapy by multiple daily sessions | Q67315713 |
| | Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy | Q67546338 |
| | Time-dose relationships for the cure of an experimental rat tumor with fractionated radiation | Q67826758 |
| | Optimum fractionation of the C3H mouse mammary carcinoma using x-rays, the hypoxic-cell radiosensitizer Ro-07-0582, or fast neutrons | Q67834968 |
| | The EORTC hyperfractionation trial | Q67984669 |
| | Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy | Q67984672 |
| | Radiotherapy of the rhabdomyosarcoma R1H of the rat: the influence of the number of fractions on tumor and skin response | Q68268285 |
| | Hyperfractionation for head and neck cancer | Q68290862 |
| | Renal Damage in the Mouse: The Response to Very Small Doses per Fraction | Q68379735 |
| | Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: an EORTC randomized trial | Q68430303 |
| | Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer | Q68637467 |
| | Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer | Q68872807 |
| | Renal damage in the mouse: the effect of d(4)-Be neutrons | Q68973840 |
| | 5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma | Q69424377 |
| | Fractionation Scheme with Low Individual Doses in Irradiation of Carcinoma of the Mouth | Q69655943 |
| | Hyperfractionated radiotherapy in the treatment of squamous cell carcinomas of the supraglottic larynx | Q69785268 |
| P433 | issue | 1 | |
| P304 | page(s) | 1-21 | |
| P577 | publication date | 1997-04-01 | |
| P1433 | published in | Radiotherapy and Oncology | Q14251029 |
| P1476 | title | Hyperfractionation: where do we stand? | |
| P478 | volume | 43 | |